WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics, today announced that members of the Company’s senior management will present at the 29th Annual J.P. Morgan Healthcare Conference. Management will provide an overview of the Company, including a commercial update for FOLOTYN® (pralatrexate injection) in relapsed or refractory peripheral T-cell lymphoma, as well as an update on the Company’s plans for FOLOTYN in advanced non-small cell lung cancer.
